Market Overview

Rockwell Medical to Discuss Top-Line Results From SFP Phase 3 CRUISE-1 Efficacy Study


Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, will host a conference call tomorrow, Wednesday July 10 at 8:00am EDT to review top-line results from their Phase 3 (CRUISE-1) efficacy study of SFP, the Company's late-stage investigational iron-delivery drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis. Rockwell will announce the top-line results tomorrow morning prior to the call.

Posted-In: News FDA


Related Articles (RMTI)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Albemarle announces quarterly dividend of 24c

Will Barnes & Noble's $129 Nook Sell as Fast as Hewlett-Packard's $99 TouchPad? (BKS, HPQ)